8-K: PDS Biotech Announces Positive 36-Month Survival Data for Cervical Cancer Treatment

PDS Biotechnology reports an 84.4% overall survival rate at 36 months for locally advanced cervical cancer patients treated with Versamune HPV and chemoradiation in a Phase 2 trial.

Summary

• PDS Biotechnology announced updated results from their IMMUNOCERV Phase 2 clinical trial.
• The trial evaluated Versamune HPV in combination with chemoradiation for treating locally advanced cervical cancer.
• The study included 17 high-risk patients with large tumors.
• The 36-month overall survival rate was 84.4% for all patients.
• The 36-month overall survival rate was 100% for the eight patients who received all five doses of Versamune HPV.
• The 36-month progression-free survival rate was 74.9% for all patients.
• The 36-month progression-free survival rate was 100% for the eight patients who received all five doses of Versamune HPV.
• A complete metabolic response was achieved in 88% (15/17) of patients.
• Versamune HPV was found to be safe and well-tolerated, with injection site reactions being the most common side effect.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with significant improvements in survival rates compared to historical data. The treatment appears safe and well-tolerated, which is encouraging. However, the small sample size and the need for further trials temper the overall optimism.

Positives

• The study showed a significant improvement in 36-month overall survival compared to historical data.
• The 100% overall and progression-free survival rates for patients receiving all five doses of Versamune HPV are very promising.
• The high rate of complete metabolic response suggests the treatment is effective.
• The treatment was well-tolerated with manageable side effects.

Negatives

• Injection site reactions were common, occurring in 71% of patients.
• One patient experienced a Grade 3 urticarial allergic reaction.
• One patient experienced Grade 2 pain.

Risks

• The study was conducted on a small sample size of 17 patients.
• The trial was closed early due to a change in the standard of care, which may limit the generalizability of the results.
• The long-term efficacy and safety of Versamune HPV need to be further evaluated in larger trials.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.

Future Outlook

PDS Biotech plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers and further investigation of Versamune HPV in cervical cancer in combination with pembrolizumab is warranted.

Management Comments

• Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech, stated that the data from the Phase 2 IMMUNOCERV trial demonstrate compelling clinical activity and a promising safety profile.
• He also noted that Versamune HPV appears to work in combination with a variety of therapeutic agents to generate clinical responses and promote improved survival in patients with minimal toxicity.

Industry Context

The announcement is significant as there are currently no FDA-approved HPV-targeted immunotherapies for cervical cancer, highlighting the potential of Versamune HPV to address an unmet medical need. The results position PDS Biotech as a potential leader in the development of HPV-targeted immunotherapies.

Comparison to Industry Standards

• The historical 36-month overall survival rate for locally advanced cervical cancer treated with chemoradiation is approximately 64%, while the PDS Biotech trial showed 84.4% overall survival.
• The historical 36-month progression-free survival rate for locally advanced cervical cancer treated with chemoradiation is approximately 61%, while the PDS Biotech trial showed 74.9% progression-free survival.
• These results compare favorably to the standard of care, suggesting a potential improvement in patient outcomes.
• The study results are particularly notable when compared to the 1999 Rose study published in the New England Journal of Medicine which showed a 36 month survival rate of 64%.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably, potentially increasing the company's stock value.
• Patients with locally advanced cervical cancer may benefit from this new treatment option.
• The company's employees may be motivated by the positive results and the potential for future success.

Next Steps

• PDS Biotech plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers.
• Further investigation of Versamune HPV in cervical cancer in combination with pembrolizumab is warranted.

Key Dates

Keywords

cervical cancer, immunotherapy, Versamune HPV, PDS0101, chemoradiation, clinical trial, overall survival, progression-free survival, metabolic response, HPV